BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 37191353)

  • 1. Visualizing Galectin-3 Binding Protein Expression with ImmunoPET.
    Keinänen O; Sarrett SM; Delaney S; Rodriguez C; Dayts EJ; Capone E; Sauniere F; Ippoliti R; Sala G; Iacobelli S; Zeglis BM
    Mol Pharm; 2023 Jun; 20(6):3241-3248. PubMed ID: 37191353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Site-Specific Photoaffinity Bioconjugation for the Creation of
    Delaney S; Nagy Á; Karlström AE; Zeglis BM
    Mol Imaging Biol; 2023 Dec; 25(6):1104-1114. PubMed ID: 37052759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lysine-Directed Site-Selective Bioconjugation for the Creation of Radioimmunoconjugates.
    Sarrett SM; Rodriguez C; Rymarczyk G; Hosny MM; Keinänen O; Delaney S; Thau S; Krantz BA; Zeglis BM
    Bioconjug Chem; 2022 Sep; 33(9):1750-1760. PubMed ID: 35946495
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Fung K; Vivier D; Keinänen O; Sarbisheh EK; Price EW; Zeglis BM
    Molecules; 2020 May; 25(10):. PubMed ID: 32429033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of DFO and DFO* conjugated to trastuzumab-DM1 for complexing
    Cho H; Al-Saden N; Lam H; Möbus J; Reilly RM; Winnik MA
    Nucl Med Biol; 2020; 84-85():11-19. PubMed ID: 31931305
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Price EW; Carnazza KE; Carlin SD; Cho A; Edwards KJ; Sevak KK; Glaser JM; de Stanchina E; Janjigian YY; Lewis JS
    J Nucl Med; 2017 Sep; 58(9):1386-1394. PubMed ID: 28280216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and Comparative
    Sharma SK; Adumeau P; Keinänen O; Sisodiya V; Sarvaiya H; Tchelepi R; Korsen JA; Pourat J; Edwards KJ; Ragupathi A; Hamdy O; Saunders LR; Rudin CM; Poirier JT; Lewis JS; Zeglis BM
    Bioconjug Chem; 2021 Jul; 32(7):1255-1262. PubMed ID: 33835770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct comparison of the in vitro and in vivo stability of DFO, DFO* and DFOcyclo* for
    Raavé R; Sandker G; Adumeau P; Jacobsen CB; Mangin F; Meyer M; Moreau M; Bernhard C; Da Costa L; Dubois A; Goncalves V; Gustafsson M; Rijpkema M; Boerman O; Chambron JC; Heskamp S; Denat F
    Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1966-1977. PubMed ID: 31161258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immuno-PET Imaging of CD30-Positive Lymphoma Using 89Zr-Desferrioxamine-Labeled CD30-Specific AC-10 Antibody.
    Rylova SN; Del Pozzo L; Klingeberg C; Tönnesmann R; Illert AL; Meyer PT; Maecke HR; Holland JP
    J Nucl Med; 2016 Jan; 57(1):96-102. PubMed ID: 26514172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A radiopharmaceutical [
    Tang Y; Hu Y; Liu W; Chen L; Zhao Y; Ma H; Yang J; Yang Y; Liao J; Cai J; Chen Y; Liu N
    Nucl Med Biol; 2019 Mar; 70():23-31. PubMed ID: 30826708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo.
    Holland JP; Divilov V; Bander NH; Smith-Jones PM; Larson SM; Lewis JS
    J Nucl Med; 2010 Aug; 51(8):1293-300. PubMed ID: 20660376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Influence of Glycans-Specific Bioconjugation on the FcγRI Binding and
    Vivier D; Fung K; Rodriguez C; Adumeau P; Ulaner GA; Lewis JS; Sharma SK; Zeglis BM
    Theranostics; 2020; 10(4):1746-1757. PubMed ID: 32042334
    [No Abstract]   [Full Text] [Related]  

  • 13. A Systematic Evaluation of Antibody Modification and
    Sharma SK; Glaser JM; Edwards KJ; Khozeimeh Sarbisheh E; Salih AK; Lewis JS; Price EW
    Bioconjug Chem; 2021 Jul; 32(7):1177-1191. PubMed ID: 32197571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the octadentate bifunctional chelator DFO*-pPhe-NCS and the clinically used hexadentate bifunctional chelator DFO-pPhe-NCS for
    Vugts DJ; Klaver C; Sewing C; Poot AJ; Adamzek K; Huegli S; Mari C; Visser GWM; Valverde IE; Gasser G; Mindt TL; van Dongen GAMS
    Eur J Nucl Med Mol Imaging; 2017 Feb; 44(2):286-295. PubMed ID: 27573793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Light-Induced Radiosynthesis of
    Klingler S; Fay R; Holland JP
    J Nucl Med; 2020 Jul; 61(7):1072-1078. PubMed ID: 31924725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Site-specifically labeled
    Kristensen LK; Christensen C; Jensen MM; Agnew BJ; Schjöth-Frydendahl C; Kjaer A; Nielsen CH
    Theranostics; 2019; 9(15):4409-4420. PubMed ID: 31285769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Zirconium-89 labeled panitumumab: a potential immuno-PET probe for HER1-expressing carcinomas.
    Bhattacharyya S; Kurdziel K; Wei L; Riffle L; Kaur G; Hill GC; Jacobs PM; Tatum JL; Doroshow JH; Kalen JD
    Nucl Med Biol; 2013 May; 40(4):451-7. PubMed ID: 23454247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DFO-Km: A Modular Chelator as a New Chemical Tool for the Construction of Zirconium-89-Based Radiopharmaceuticals.
    Salih AK; Dominguez Garcia M; Raheem SJ; Ahiahonu WK; Price EW
    Inorg Chem; 2023 Dec; 62(50):20806-20819. PubMed ID: 37751491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Positron-Emission Tomography of HER2-Positive Breast Cancer Xenografts in Mice with
    Al-Saden N; Lam K; Chan C; Reilly RM
    Mol Pharm; 2018 Aug; 15(8):3383-3393. PubMed ID: 29957952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation and selection of a lead diabody for interferon-γ PET imaging.
    Rezazadeh F; Ramos N; Saliganan AD; Barr S; Peraino N; Schomburg F; Rancour D; Viola NT
    Nucl Med Biol; 2022; 114-115():162-167. PubMed ID: 35753939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.